The News
A Chicago-based foundation is working to close one of the most persistent gaps in mental health care: the cost of ketamine therapy. As reported by The Daily Northwestern, the foundation is providing financial support to depression patients who cannot afford ketamine infusions — and who cannot afford to wait for insurance coverage that may never come. The story highlights a growing tension in mental health treatment: ketamine has demonstrated real clinical value for treatment-resistant depression, yet most commercial insurers continue to classify it as experimental and decline to cover it.
Why Insurance Coverage Has Stalled
The coverage gap for ketamine isn't an oversight — it reflects how the insurance approval process actually works. IV ketamine infusions, the most studied and widely used clinical form of the treatment, are administered using a generic drug that has been off-patent for decades. Because no single pharmaceutical company holds a proprietary stake in IV ketamine, there is little financial incentive to fund the large-scale randomized trials that insurers typically require before adding a treatment to their covered services list.
Esketamine (Spravato), the FDA-approved nasal spray version manufactured by Janssen, does have insurance coverage pathways — but it comes with its own restrictions. Patients must administer it in a certified provider's office and be monitored for two hours afterward, it requires prior authorization, and it is only approved for specific diagnoses. Many patients who respond well to IV infusions don't qualify for Spravato coverage, or find the in-office monitoring requirement logistically difficult.
The result is a two-tier system: patients with the financial means to pay out-of-pocket — infusion series typically run between $2,000 and $8,000 depending on the provider and location — can access a treatment that may work when nothing else has. Everyone else waits, often while managing severe or treatment-resistant depression.
What Nonprofit Assistance Models Look Like in Practice
The Chicago foundation's approach reflects a broader pattern emerging across the country. A small but growing number of nonprofits, patient assistance programs, and sliding-scale clinics are trying to make ketamine therapy more accessible outside of the insurance system. Some operate as standalone charitable funds. Others are attached to academic medical centers or community mental health organizations. A handful of ketamine clinics have begun offering income-based pricing or payment plans independently.
These efforts are meaningful for the patients they reach, but they don't solve the structural problem. Charitable funds are finite. Sliding-scale availability varies widely by geography. Rural and lower-income communities — where treatment-resistant depression is often more prevalent and mental health resources are already thin — are the least likely to have a foundation or specialty clinic nearby.
For patients navigating this landscape in 2026, the practical reality is that access to ketamine therapy still depends heavily on where you live, what you earn, and how persistent you're willing to be in advocating for yourself within a fragmented system.
Key Takeaway for Patients
If cost is a barrier to ketamine treatment, it's worth asking your provider directly about financial assistance options before assuming none exist. Some clinics offer payment plans or income-based pricing that isn't advertised. Patient assistance programs, local mental health foundations, and academic medical center programs are also worth researching in your area. Insurance coverage for IV ketamine remains unlikely in the near term, but the landscape for partial assistance is broader than many patients realize.
The Bigger Picture
Stories like this one from Chicago matter not just for the individuals they help, but for what they signal about where mental health care is headed. The fact that foundations are stepping in to fund a treatment that clinicians broadly recognize as effective — while insurers remain on the sidelines — illustrates a failure of the coverage system to keep pace with clinical evidence. That gap creates pressure over time. As more patients and providers document outcomes, as more psychiatrists incorporate ketamine into their practice, and as more stories of access inequity become public, the actuarial and political calculus for insurers will eventually shift.
Whether that shift happens through regulatory action, employer health plan mandates, or gradual insurer policy updates remains to be seen. In the meantime, the gap is real, the need is urgent, and the patients who can't wait are fortunate when a foundation is there to meet them.
Share